<DOC>
	<DOCNO>NCT00610935</DOCNO>
	<brief_summary>The purpose study determine safety effectivess single intramuscular injection peramivir treatment subject acute , uncomplicated influenza .</brief_summary>
	<brief_title>Intramuscular Peramivir Subjects With Uncomplicated Acute Influenza</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Peramivir</mesh_term>
	<criteria>Male nonpregnant female subject age ≥18 year . A positive Influenza A and/or B Rapid Antigen Test ( RAT ) perform commercially available test kit adequate anterior nasal specimen , accordance manufacturer 's instruction . A negative initial RAT repeat within onehour . Presence fever time screen ≥38.0 ºC ( ≥100.4 ºF ) take orally , ≥38.5 ºC ( ≥101.2 ºF ) take rectally . A subject selfreport history fever feverishness within 24 hour prior screen also qualify enrollment absence document fever time screen . Presence least one respiratory symptom ( cough , sore throat , nasal symptom ) least moderate severity . Presence least one constitutional symptom ( myalgia [ ache pain ] , headache , feverishness , fatigue ) least moderate severity . Onset symptoms 48 hour presentation screen . Written informed consent . Women pregnant breastfeeding . Presence clinically significant sign acute respiratory distress . History severe chronic obstructive pulmonary disease ( COPD ) severe persistent asthma ( See section 15.2 ) . History congestive heart failure require daily pharmacotherapy symptom consistent New York Heart Association Class III IV functional status within past 12 month . Screening ECG suggests acute ischemia presence medically significant dysrhythmia . History chronic renal impairment require hemodialysis and/or know suspected moderate severe renal impairment ( actual estimate creatinine clearance &lt; 50 mL/min ) . Clinical evidence worsen chronic medical condition ( temporally associate onset symptom influenza ) , investigator 's opinion , indicate find ( ) could represent complication influenza . Current clinical evidence , include clinical sign and/or symptom consistent otitis , bronchitis , sinusitis and/or pneumonia , active bacterial infection body site require therapy oral systemic antibiotic . Presence immunocompromised status due chronic illness , previous organ transplant , use immunosuppressive medical therapy would include oral systemic treatment &gt; 10 mg prednisone equivalent daily basis within 30 day screen . Currently receive treatment viral hepatitis B viral hepatitis C. Presence know HIV infection CD4 count &lt; 350 cell/mm3 . Current therapy oral warfarin systemic anticoagulant . Receipt dose rimantadine , amantadine , zanamivir , oseltamivir 7 day prior screen . Immunized influenza live attenuate virus vaccine ( FluMist® ) previous 21 day . Immunized influenza inactivate virus vaccine within previous 14 day . Receipt intramuscular injection within previous 14 day . History alcohol abuse drug addiction within 1 year prior admission study . Participation previous study intramuscular intravenous peramivir previous participation study . Participation study investigational drug device within last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Subjects uncomplicated acute influenza</keyword>
</DOC>